Melanoma antigen preferentially expressed in tumors (100-108)

Melanoma antigen preferentially expressed in tumors (100-108) is a synthetic peptide fragment corresponding to amino acids 100 through 108 of the MAGE-A1 protein, a member of the melanoma antigen gene (MAGE) family. This peptide is recognized for its immunogenic properties and its relevance in tumor immunology, particularly in the context of antigen-specific T cell responses. As a defined epitope, it serves as a valuable tool for dissecting the molecular mechanisms underlying tumor recognition by the immune system and for advancing research in cancer immunotherapy. Its sequence specificity and well-characterized immunological profile make it an important reagent for investigations into antigen processing, presentation, and immune targeting in melanoma and other malignancies expressing MAGE-A1.

Epitope mapping: The peptide is widely used in studies focused on the identification and characterization of T cell epitopes within tumor-associated antigens. By providing a precise sequence derived from the MAGE-A1 protein, it enables researchers to assess the specificity and cross-reactivity of cytotoxic T lymphocytes (CTLs) and helper T cells. Such mapping is crucial for understanding immune recognition patterns and for the rational design of immunotherapeutic strategies targeting tumor antigens.

Immunological assay development: As a well-defined antigenic peptide, the fragment is instrumental in the development and validation of immunological assays, such as enzyme-linked immunospot (ELISpot) and intracellular cytokine staining (ICS). These assays utilize the peptide to stimulate T cells in vitro, allowing for the quantification and functional analysis of antigen-specific immune responses. Its use in assay systems supports the standardization of immune monitoring protocols in preclinical and translational research settings.

T cell activation studies: The peptide serves as a model antigen for in vitro stimulation of T lymphocytes isolated from human donors or experimental animal models. By exposing immune cells to this defined sequence, investigators can study the activation, proliferation, and effector functions of antigen-specific T cells. This approach is fundamental for elucidating the mechanisms of T cell-mediated tumor immunity and for screening potential immunomodulatory compounds.

Antigen processing research: The defined sequence of the peptide provides a controlled substrate for examining the pathways of antigen processing and presentation by major histocompatibility complex (MHC) molecules. Researchers can utilize it to investigate the efficiency of peptide loading onto MHC class I molecules, the stability of peptide-MHC complexes, and the subsequent recognition by T cell receptors. Insights gained from such studies inform the optimization of peptide-based vaccine design and the identification of factors influencing immune recognition in the tumor microenvironment.

Peptide-based vaccine research: The fragment is frequently employed in the preclinical evaluation of peptide-based cancer vaccines. Its immunogenic properties enable the assessment of vaccine formulations intended to elicit robust and specific T cell responses against tumor antigens. By serving as a model epitope, it facilitates the comparison of adjuvants, delivery systems, and immunization protocols, thereby advancing the rational development of next-generation cancer immunotherapies that leverage tumor-associated antigens.

1. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review

2. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

3. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

4. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

5. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance